Premium
Interferon α in the treatment of chronic hepatitis C in children: a metanalysis
Author(s) -
Ciommo V. Di,
Russo P.,
Ravà L.,
Caprino L.
Publication year - 2003
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.2003.00420.x
Subject(s) - medicine , chronic hepatitis , hepatitis c , clinical trial , interferon , alpha interferon , liver disease , alanine transaminase , adverse effect , transaminase , bdna test , gastroenterology , hepatitis c virus , immunology , virus , biochemistry , chemistry , enzyme
Summary. Children with chronic hepatitis C may be ideal candidates for treatment with interferon alpha (IFN α ) as they have liver disease at an early stage. However, adverse drug reactions need to be considered. The aim of this study was to conduct a systematic review of literature on interferon therapy of chronic hepatitis C in children, and to perform a metanalysis of pooled data. A computerized search gave 18 articles on IFN α therapy in children with chronic hepatitis C; after exclusion of uncontrolled trials and of trials including patients with comorbidities, data from two studies could be pooled (48 patients). The outcomes assessed were biochemical, defined as normalization of alanine transaminase, and virologic, defined as HCV‐RNA loss, both sustained at 24 months after enrolment. Results of the studies were homogenous. Risk difference was 37% (95%CI: 12.9–61) in favour of IFN α treated children for sustained biochemical response, and 36.8% (95%CI: 14.3–59.3) in favour of treated children for sustained HCV clearance, respectively. The differences were highly significant ( P = 0.007 and P = 0.004, respectively). The histological end‐point, as well as side‐effects, could not be analysed, due to lack of data. This review identifies the poor methodology of the majority of the published trials. The study provides support for the efficacy of IFN α in improving both biochemical and virologic outcomes in chronic hepatitis C in children, but evidence is confined to these surrogate end‐points.